A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
05/23/2019 - 03/31/2023 (PI)Corbus Pharmaceuticals Holdings, Inc.
Scleroderma Cyclophosphmide or Transplantation (SCOT) Study
08/01/2011 - 10/31/2022 (Subcontract PI)Duke University NIH NIAID
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
09/22/2017 - 08/31/2022 (Subcontract PI)University of Pittsburgh NIH NIAMS5P50AR060780-07
Protocol #201247, A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics pharmacodyna
08/30/2017 - 08/29/2022 (PI)GlaxoSmithKline LLC
A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B (TGFB) Inhibitor, in Patients with Diffuse Cutaneous Systemic
02/25/2019 - 02/24/2022 (PI)Formation Biologics Corp.
Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 01/31/2022 (Co-Investigator of Sub-Project / SP)Benaroya Research Institute at Virginia Mason NIH NIAID2UM1AI109565-08
OPsumit Historical USers cohort study (OrPHeUS). a Multicenter. retrospective chart review of first-time Opsumit® (macitentan) users in the United States
02/06/2018 - 12/31/2021 (PI)Actelion Pharmaceuticals, Ltd.
United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2021 (PI)United States Pulmonary Hypertension Scientific Registry
US-based, observation, drug registry of Opsumit (macitentan) new users in clinical practice
01/16/2015 - 12/08/2021 (PI)Actelion Pharmaceuticals, Ltd.
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2021 (PI)Corbus Pharmaceuticals Holdings, Inc.
Showing 10 of 49 results.
Show All Results